Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 33 articles: HTML format

Single Articles

April 2024
1. MOSER R, Pfeiffer S, Cala L, Klein E, et al
   Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
   J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
   PubMed     Abstract available
   
   
   
2. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
   Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
   J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
   PubMed     Abstract available
   
   
   March 2024
3. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
   Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
   J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
   PubMed     Abstract available
   
   
   
4. SAHIN E, Kus T, Aytekin A, Uzun E, et al
   (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
   J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
   PubMed     Abstract available
   
   
   February 2024
5. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
   Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
   J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
   PubMed     Abstract available
   
   
   
6. GEBHART G, Piccart M, Mankoff D
   Molecular Imaging in Breast Cancer: Martine Piccart and Geraldine Gebhart Talk with David Mankoff About 2 Generations of Research.
   J Nucl Med. 2024 Feb 8:jnumed.124.267461. doi: 10.2967/jnumed.124.267461.
   PubMed    
   
   
   
7. JACENE H, Dietsche E, Specht J
   The Current and Future Roles of Precision Oncology in Advanced Breast Cancer.
   J Nucl Med. 2024 Feb 1:jnumed.122.264882. doi: 10.2967/jnumed.122.264882.
   PubMed     Abstract available
   
   
   
8. GONDRY O, Caveliers V, Xavier C, Raes L, et al
   Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
   J Nucl Med. 2024;65:178-184.
   PubMed     Abstract available
   
   
   January 2024
9. YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
   First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
   J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
   PubMed     Abstract available
   
   
   December 2023
10. MANKOFF D, Balogova S, Dunnwald L, Dehdashti F, et al
    Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16alpha-[(18)F]Fluoro-17beta-Estradiol PET.
    J Nucl Med. 2023 Dec 7:jnumed.123.266938. doi: 10.2967/jnumed.123.266938.
    PubMed     Abstract available
    
    
    November 2023
11. CHEN L, Zheng S, Chen L, Xu S, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.
    J Nucl Med. 2023 Nov 2:jnumed.123.266079. doi: 10.2967/jnumed.123.266079.
    PubMed     Abstract available
    
    
    
12. GEBHART G
    (18)F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
    J Nucl Med. 2023;64:1697-1698.
    PubMed    
    
    
    September 2023
13. ALTENA R, Af Buren S, Tran T, Axelsson R, et al
    HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266101. doi: 10.2967/jnumed.123.266101.
    PubMed    
    
    
    
14. SEBAN RD
    Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266490. doi: 10.2967/jnumed.123.266490.
    PubMed    
    
    
    August 2023
15. HENNESSY MA, Leal JP, Huang CY, Solnes LB, et al
    Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
    J Nucl Med. 2023 Aug 31:jnumed.123.265853. doi: 10.2967/jnumed.123.265853.
    PubMed     Abstract available
    
    
    
16. MOHR P, van Sluis J, Providencia L, van Snick JH, et al
    Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for (89)Zr-Trastuzumab.
    J Nucl Med. 2023 Aug 3:jnumed.123.265621. doi: 10.2967/jnumed.123.265621.
    PubMed     Abstract available
    
    
    July 2023
17. ALHUSEINALKHUDHUR A, Lindman H, Liss P, Sundin T, et al
    Human Epidermal Growth Factor Receptor 2-Targeting [(68)Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer.
    J Nucl Med. 2023 Jul 13:jnumed.122.265364. doi: 10.2967/jnumed.122.265364.
    PubMed     Abstract available
    
    
    June 2023
18. BROWN EL, Shmuel S, Mandleywala K, Panikar SS, et al
    Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    J Nucl Med. 2023 Jun 29:jnumed.122.265172. doi: 10.2967/jnumed.122.265172.
    PubMed     Abstract available
    
    
    
19. WATABE T, Naka S, Tatsumi M, Kamiya T, et al
    Initial Evaluation of [(18)F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions.
    J Nucl Med. 2023 Jun 2:jnumed.123.265486. doi: 10.2967/jnumed.123.265486.
    PubMed     Abstract available
    
    
    May 2023
20. SEBAN RD, Champion L, Bellesoeur A, Vincent-Salomon A, et al
    Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.
    J Nucl Med. 2023 May 25:265434. doi: 10.2967/jnumed.123.265434.
    PubMed    
    
    
    April 2023
21. DONOHOE KJ, Carroll BJ, Chung DKV, Dibble EH, et al
    Summary: Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema.
    J Nucl Med. 2023;64:525-528.
    PubMed     Abstract available
    
    
    March 2023
22. ULANER GA, Mankoff DA, Clark AS, Fowler AM, et al
    Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16alpha-(18)F-Fluoro-17beta-Fluoroestradiol.
    J Nucl Med. 2023;64:351-354.
    PubMed     Abstract available
    
    
    January 2023
23. FENG Y, Meshaw R, Zhao XG, Jannetti S, et al
    Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose (211)At-Labeled Anti-HER2 Single-Domain Antibody Fragment.
    J Nucl Med. 2023;64:124-130.
    PubMed     Abstract available
    
    
    November 2022
24. LUMISH MA, Maron SB, Paroder V, Chou JF, et al
    Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264470. doi: 10.2967/jnumed.122.264470.
    PubMed     Abstract available
    
    
    
25. BACKHAUS P, Burg MC, Asmus I, Pixberg M, et al
    Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264871. doi: 10.2967/jnumed.122.264871.
    PubMed     Abstract available
    
    
    October 2022
26. VOGSEN M, Harbo F, Jakobsen NM, Nissen HJ, et al
    Response monitoring in metastatic breast cancer - a prospective study comparing (18)F-FDG PET/CT with conventional CT.
    J Nucl Med. 2022 Oct 7. pii: jnumed.121.263358. doi: 10.2967/jnumed.121.263358.
    PubMed     Abstract available
    
    
    September 2022
27. MORAWITZ J, Sigl B, Rubbert C, Bruckmann NM, et al
    Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on (18)F-FDG PET/MRI and machine-learning.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264138. doi: 10.2967/jnumed.122.264138.
    PubMed     Abstract available
    
    
    August 2022
28. SHIN J, Parker MFL, Zhu I, Alanizi A, et al
    Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264284. doi: 10.2967/jnumed.122.264284.
    PubMed     Abstract available
    
    
    
29. SINGARAVELU I, Spitz H, Mahoney M, Dong Z, et al
    Antiandrogen Therapy Radiosensitizes Androgen Receptor-Positive Cancers to (18)F-FDG.
    J Nucl Med. 2022;63:1177-1183.
    PubMed     Abstract available
    
    
    June 2022
30. ZHOU R, Choi H, Cao J, Pantel A, et al
    (18)F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264152. doi: 10.2967/jnumed.122.264152.
    PubMed     Abstract available
    
    
    May 2022
31. OKAZAWA H
    ER Imaging for Estrogen-Related Tumors Is Bothersome but Useful.
    J Nucl Med. 2022;63:700-701.
    PubMed    
    
    
    December 2021
32. SEBAN RD, Richard C, Nascimento-Leite C, Ghidaglia J, et al
    Absolute lymphocyte count after COVID-19 vaccination is associated with vaccine-induced hypermetabolic lymph nodes on (18)F-FDG PET/CT: a focus in breast cancer care.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.263082. doi: 10.2967/jnumed.121.263082.
    PubMed     Abstract available
    
    
    
33. MORTIMER JE, Bading JR, Frankel PH, Caroll M, et al
    Use of (64)Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262940. doi: 10.2967/jnumed.121.262940.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.